Splinting as First-Line Treatment for Trigger Finger
Yes, splinting is a reasonable and effective first-line treatment for trigger finger, offering comparable pain relief and functional improvement to corticosteroid injections without the associated risks of skin atrophy or infection. 1, 2
Evidence Supporting Splinting
The most recent high-quality evidence demonstrates that splinting alone achieves clinically meaningful outcomes:
- Success rates up to 97% in short-term studies (within 1 year) 1
- Equivalent pain reduction compared to steroid injection at 6,12, and 52 weeks, with no clinically important differences between treatments 2
- Similar functional improvement measured by Michigan Hand Outcomes Questionnaire scores across all timepoints 2
Optimal Splinting Protocol
Based on the strongest evidence, the proximal interphalangeal (PIP) joint blocking orthosis worn continuously for at least 6 weeks is the most effective approach 1. This specific splint type:
- Provides superior pain reduction compared to metacarpophalangeal (MCP) joint blocking orthoses
- Delivers better functional outcomes
- Achieves higher patient satisfaction due to improved comfort and aesthetics
- Results in greater adherence and wear time 1
Key implementation details:
- Wear the splint 24 hours per day for maximum effectiveness 1
- Continue for 6 consecutive weeks minimum 2, 3
- The splint should maintain the joint in neutral position 2
Comparison with Other Treatments
A 2023 randomized controlled trial directly comparing treatments found 2:
- Splinting alone = Steroid injection alone = Combined therapy in terms of pain relief and functional improvement
- No added benefit from combining splinting with steroid injection
- Therefore, the combination approach is disadvantageous as it adds intervention burden without additional benefit
Another study showed that adding splinting to steroid injection does provide some incremental benefit in reducing pain (p=0.013) and symptom severity (p=0.047) at 3 months 4, though the 2023 study with longer follow-up found no clinically important differences 2.
Clinical Algorithm
Start with splinting when:
- Patient prefers to avoid injections
- Mild to moderate severity (Quinnell stages I-II)
- First presentation without prior treatment
- Patient can commit to continuous wear
Consider steroid injection or surgery when:
- Splinting fails after 6-12 weeks
- Severe disease (Quinnell stage III-IV)
- Patient unable to tolerate continuous splint wear
- Multiple previous failed conservative treatments
Important Caveats
Adherence is the primary challenge with splinting therapy 1. Success requires:
- Patient education about the importance of continuous wear
- Proper splint fitting by trained personnel
- Regular monitoring for skin breakdown or adverse effects
- Patient empowerment to discontinue if complications arise
Avoid splinting in functional neurological disorders where immobilization may worsen symptoms through increased attention to the area, accessory muscle use, and learned non-use 5. However, this caveat does not apply to mechanical trigger finger.
Guideline Support
The 2014 European HANDGUIDE multidisciplinary consensus identified splinting as a suitable first-line treatment option alongside corticosteroid injections 6. Treatment selection should be based on:
- Disease severity and duration
- Previous treatments received
- Patient preference regarding invasive procedures
The evidence strongly supports splinting as first-line therapy, particularly using a PIP blocking orthosis worn continuously for 6 weeks, offering equivalent outcomes to steroid injection without procedural risks.